Drawing on MRC Technology’s commercialisation expertise in drug discovery, the project focusses on bringing to clinic more effective pain treatments arising from the work of Dr Cader’s group in identifying KCNK18, the first gene underlying typical migraine.
Read more (MRC Technology's website)